IFNA1 and viral infectious disease: In such cases, employing IFN response inhibitors, such as TPCA‐I (an IKK‐2 inhibitor) or Ruxolitinib (a JAK1/2 inhibitor), can augment the efficiency of oncolytic viral infections.99